Accreditation/Credit Designation
Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Acknowledgment of Support
This activity is supported by an educational grant from Amgen, Inc.
Cancer Summaries and Commentaries®: Updates From Chicago on the Treatment of Lung Cancer
Release Date: October 15, 2021
Expiration Date: October 15, 2022
Activity Overview
Acknowledgement of Commercial Support
This activity is supported by an educational grant from Amgen, Inc.
Instructions for This Activity and Receiving Credit
You may immediately download your certificate. |
Target Audience
This educational activity is directed toward medical oncologists and fellows who treat patients with lung cancer. Surgical oncologists, radiation oncologists, pathologists, nurse practitioners, nurses, physician assistants, pharmacists, researchers, and other health care professionals interested in the treatment of lung cancer will be invited to participate.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:- Identify contemporary strategies in testing for predictive and prognostic biomarkers that guide decision-making in lung cancer management.
- Assess recently reported safety and efficacy data applicable to the care of patients with lung cancer.
- Place recent evidence from clinical trials in the context of evolving treatment paradigms in lung cancer care
Faculty, Staff, and Planners’ Disclosures
The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible entities
Faculty
Physician
Dana-Farber Cancer Institute
Instructor of Medicine
Harvard Medical School
Boston, MA
Disclosures: Consultant: Daiichi-Sankyo, AstraZeneca, Takeda, Medtronic, Lilly, Jazz Pharmaceuticals, Blueprint Medicines
PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.
Login or Register to Start Activity
Please use the form below to Register or Log In to begin Activity.